Grigioni W F, Garbisa S, D'Errico A, Baccarini P, Stetler-Stevenson W G, Liotta L A, Mancini A M
Center for Cancer Research, Bologna University, Italy.
Am J Pathol. 1991 Mar;138(3):647-54.
Invasion and metastasis requires a series of interactions between malignant cells and the extracellular matrix (ECM). Antigen markers that relate to these interactions were evaluated for prognostic correlation in human hepatocellular carcinoma. Basement membrane type IV collagen (cIV), type IV collagenase (cIVase), laminin, and laminin receptors (LRs)--all ECM antigens previously proposed to be modulated in association with tumor aggressiveness--were immunohistochemically investigated in 30 cases of hepatocellular carcinomas (HCCs). The pattern of antigen expression was correlated with 1) 36 months' clinical follow-up and 2) the pathologic grade. As a means of estimating the proliferation fraction, an additional antigen, Ki67, was also studied in this series. There were major differences in the distribution of cIV and laminin, and in the quantity of cIVase-, LR-, and Ki67-positive cells associated with grade and prognosis. A smaller quantity of cIV and laminin and a higher number of cIVase-, LR-, and Ki67-positive cells were detected in the poorly differentiated compared with the well-differentiated HCCs. The tumors with lower immunoreactivity for cIV and laminin components accompanied by a higher number of cIVase-, LR-, and Ki67-positive cells fall into a group with the poorest overall survival (P less than 0.006). The panel of antigens is proposed as a useful prognostic tool for evaluating HCC tumor aggressiveness.
侵袭和转移需要恶性细胞与细胞外基质(ECM)之间进行一系列相互作用。对与这些相互作用相关的抗原标志物进行了评估,以探讨其与人类肝细胞癌预后的相关性。对30例肝细胞癌(HCC)进行免疫组织化学研究,检测基底膜IV型胶原(cIV)、IV型胶原酶(cIVase)、层粘连蛋白和层粘连蛋白受体(LRs),这些都是先前提出的与肿瘤侵袭性相关的ECM抗原。抗原表达模式与1)36个月的临床随访结果以及2)病理分级相关。作为评估增殖分数的一种方法,本研究系列还对另一种抗原Ki67进行了研究。cIV和层粘连蛋白的分布以及与分级和预后相关的cIVase、LR和Ki67阳性细胞数量存在显著差异。与高分化HCC相比,低分化HCC中检测到的cIV和层粘连蛋白数量较少,而cIVase、LR和Ki67阳性细胞数量较多。cIV和层粘连蛋白成分免疫反应性较低且cIVase、LR和Ki67阳性细胞数量较多的肿瘤总体生存率最差(P<0.006)。该抗原组合被认为是评估HCC肿瘤侵袭性的一种有用的预后工具。